Opinion

Video

Expert Insights into Investigation Therapies for CLL

Author(s):

Catherine C. Coombs, MD,Brian T. Hill, MD, PhD

Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™
Video

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

May 9th 2025 - Jun 14th 2025

online-activity
View More
Proactive Adverse Event Management for HER2+ BTC Treatments
Video

Proactive Adverse Event Management for HER2+ BTC Treatments

May 8th 2025 - May 9th 2026

online-activity
View More
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina
Video

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

May 2nd 2025 - Jun 7th 2025

online-activity
View More
Related Content
Rami Komrokji, MD, vice chair, Malignant Hematology Department, senior member, Malignant Hematology and Experimental Therapeutics Program, Moffitt Cancer Center; professor, medicine & oncologic sciences, College of Medicine, University of South Florida
May 13th 2025

Genetic Insights and Novel Trial Designs Contribute to an Era of Individualized MDS Management

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, the Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Susan M. O'Brien, MD, associate director, Clinical Science, Chao Family Comprehensive Cancer Center, medical director, Sue & Ralph Stern Center for Clinical Trials & Research, professor, medicine, Division of Hematology/Oncology, University of California Irvine School of Medicine
December 31st 2024

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

Nicole Lamanna, MD
May 9th 2025

Patient Symptoms and Disease Features Guide Pirtobrutinib Use in R/R CLL

Onyee Chan, MD, hematologist/oncologist, Moffitt Cancer Center Magnolia Campus; Bradley D. Hunter, MD, medical director, Oncology, director, Immune Effector Cell Therapy, Intermountain Healthcare
December 24th 2024

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

Arielle Heeke, MD
Published: May 2nd 2025 | Updated: May 6th 2025

Adjuvant CDK4/6 Inhibition Gains Further Ground in HR+/HER2– Early Breast Cancer With Ribociclib Approval

Adam Calaway, MD, MPH
April 30th 2025

Testicular Cancer Awareness Month: Early Detection and Risk Assessment Pave the Way Toward Optimal Outcomes